Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

or parkinsonism. Both of these scales documented minimal symptoms at baseline and there was no worsening during the six weeks of treatment. Clinical hematology, chemistry and ECG monitoring indicated no emergent safety signals.

There were no drug-drug interactions identified in subjects who were utilizing a range of psychotropic and other concomitant medications.

Next Steps for NBI-98854Data from the Kinect 2 study will be integrated with the Kinect study data to inform the ultimate design of the next study, Kinect 3. The Company will work with its consultants and scientific advisors to expand and refine the pharmacokinetic/pharmacodynamic models as well as to complete the remaining safety and efficacy analyses from both Kinect and Kinect 2. These data will form the basis for an End of Phase II briefing package along with the proposed Phase III protocol.

Kinect 2 Study DesignThe Kinect 2 Study was a randomized, parallel, double-blind, placebo-controlled, dose titration Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with an underlying mood disorder (e.g., bipolar disorder), schizophrenia or schizoaffective disorder, or a gastrointestinal disorder with exposure to metoclopramide. This 100 subject study assessed once-daily NBI-98854 over a six-week placebo-controlled dosing period. Half of the randomized subjects received placebo and half received NBI-98854. The NBI-98854 dosing regimen began with a once-daily dose of 25 mg for the initial two weeks. At the completion of the initial two weeks of dosing, based on certain efficacy and safety criteria, patients were titrated to a once-daily 50 mg dose, or continued on the once-daily 25 mg dose for the following two-week period. At the completion of the second two weeks of treatment another efficacy and safety assessment was performed and patients were eligible to be titrated to a once-daily 75 mg, 50 mg or 25 mg dose for the
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/19/2014)... Aug. 19, 2014   Lincor Inc. ... experience technology to New Jersey ... agreement, CarePoint Health will deploy Lincor,s PatientLINC technology ... Christ Hospital and Hoboken University Medical Center. ... of software solutions to help hospitals reach new ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder ... present a scientific poster describing an innovative diagnostic procedure ... 2014: Shedding New Light on Disease (SPEC) conference in ... Dr. Treado,s poster entitled, "Development of in vitro Diagnostics ... will be discussed during the conference poster session on ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... CINCINNATI, Ohio , June 29 Dr. Harry J. ... speaker and panel discussion participant at the 2010 Central Regional Meeting of ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants and ... chemical disciplines.   , , ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems,Ltd. (Nasdaq: DHRM ), an emerging leader in the ... ,today announced members of its Executive Management will ring the NASDAQ Stock,Market closing bell ... , , ... , , ...
Cached Medicine Technology:Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell 2Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell 3
(Date:8/20/2014)... August 20, 2014 According to an ... August 7 in the multicounty litigation (MCL) case pending ... DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 ... been dismissed without prejudice. The cases enumerated in the ... being resolved.” The Rottenstein Law Group LLP, a national ...
(Date:8/20/2014)... made it easier to predict both breast cancer ... of a unique gene. The newly found marker ... and customise a treatment regimen that is more ... scientists from A*STAR,s Institute of Molecular and Cell ... Singapore (CSI Singapore) at the National University of ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... 2014 The finalists are in for ... industry trade magazine, will honor the pharmaceutical industry’s most ... given to outstanding companies, marketers and brand managers representing ... “We are proud to announce that we received our ... double the number of submissions we received last year,” ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2
... Dec. 20 HMS Holdings Corp. (Nasdaq:,HMSY) today announced ... Conference, which will be held January 7-10, 2008 at ... http://www.newscom.com/cgi-bin/prnh/20030304/NYTU172LOGO ), Robert Holster, Chairman and CEO ... at 2:00 p.m. Pacific Time., A live broadcast ...
... to determine if treating depression improves health of ... heart ... with heart,disease are more likely to suffer from depression than those ... well understood,but it is known that depression in heart patients is ...
... THURSDAY, Dec. 20 (HealthDay News) -- Exposure to secondhand ... of developing allergies, Swedish researchers say. , A team ... by the parents of more than 4,000 families. , ... were ages two months, 12 months, 2 years and ...
... Toronto Stock Exchange Symbol: AKL, MONTREAL, Dec. ... drug development company focused on developing therapies for ... to unfavorable market,conditions, particularly in the small and ... public offering initiative. The Company is currently,contemplating other ...
... University researchers have updated their Food Guide Pyramid for ... now known as MyPyramid. The Tufts version is specifically ... and content. The Modified MyPyramid for Older Adults continues ... fluid balance, but has added additional guidance about forms ...
... WESTBROOK, Maine, Dec. 19 IDEXX Laboratories,Inc. (Nasdaq: ... the,JPMorgan 26th Annual Healthcare Conference. Jonathan W. Ayers, Chairman,President ... the Company on,Monday, January 7, 2008 at 8:00 a.m. ... Individuals can access the live audio webcast of,the presentation ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Foundation Funds Study Exploring Link between Heart Disease and Depression 2Health News:Parents' Smoking Boosts Child's Allergy Risk 2Health News:Akela Pharma provides corporate update 2Health News:Tufts researchers update their food guide pyramid for older adults 2Health News:Tufts researchers update their food guide pyramid for older adults 3
Bi-phasic peristaltic infusion pump for tumescent work....
Inquire...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
... VASER System represents a major advance ... to cosmetic procedures. Combined with precision ... emulsification, a solid grooved probe design ... System has been designed to minimize ...
Medicine Products: